Two Sigma Securities LLC Invests $449,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Two Sigma Securities LLC acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 18,589 shares of the company's stock, valued at approximately $449,000.

A number of other large investors have also added to or reduced their stakes in the stock. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. boosted its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its position in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new position in Hims & Hers Health in the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,153 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90. Following the sale, the insider now directly owns 161,497 shares in the company, valued at $5,700,844.10. This trade represents a 2.51 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Dudum sold 100,000 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the transaction, the chief executive officer now directly owns 27,918 shares of the company's stock, valued at $983,271.96. This represents a 78.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 712,998 shares of company stock valued at $27,992,450 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HIMS shares. Piper Sandler increased their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Bank of America upped their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Leerink Partners upped their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a report on Tuesday, February 25th. Finally, Morgan Stanley downgraded Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $38.08.

Hims & Hers Health Stock Down 0.1 %

Shares of NYSE:HIMS opened at $28.10 on Friday. The stock has a market capitalization of $6.24 billion, a PE ratio of 63.87 and a beta of 1.65. The firm's 50 day moving average price is $34.24 and its 200-day moving average price is $30.99. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.